CTOs on the Move


 
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.olema.com
  • 665 3rd Street Suite 250
    San Francisco, CA USA 94107
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Gaia Herbs

Gaia Herbs has established itself as the leading grower and producer of Certified Organic (COG) herbs and herbal products. Gaia Herbs strives to produce pure plant medicines of exceptional quality and purity while enriching the ecology of the earth and the health and harmony of the people that use our phyto-medicines. Gaia Herbs is a certified organic grower and nationally-branded manufacturer of liquid herbal extracts based in Western NC. Find our products at health food retailers and co-ops, natural products retail chains, and healthcare professionals. Our commitment to certified organic herbs ensures strength, purity, and efficacy of our herbal products.

TRx Pharma

TRx Pharma is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bell Pharmaceuticals

Bell Pharmaceuticals is a Belle Plaine, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novis Pharmaceuticals

Novis Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.